ICLR
ICLR clinical trials: ICON PLC
Every trial on ClinicalTrials.gov where ICON PLC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 105
- Trials linked
- 5
- As lead sponsor
- 100
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ICLR on the catalyst calendar · ICLR registry changes
- Primary completion May 2010ActualPhase 2NCT01048593Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract SurgeryICON Bioscience Inc · Inflammatory Reaction Due to Ocular Lens ProsthesisTerminatedICLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 16, 2016ActualPhase 3NCT02547623Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract SurgeryICON Bioscience Inc · CataractCompletedICLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2014ActualPhase 3NCT02006888The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract SurgeryICON Bioscience Inc · InflammationCompletedICLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2013ActualPhase 2NCT01606735Efficacy and Safety of IBI-10090 in Ocular Surgery PatientsICON Bioscience Inc · Inflammation Associated With Cataract SurgeryCompletedICLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2012ActualPhase 2NCT01214174Efficacy and Safety Study of IBI-10090 in Cataract Surgery PatientsICON Bioscience Inc · Ocular InflammationTerminatedICLRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2029Sponsor estimatePhase 3NCT07430306A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus...AstraZeneca · Systemic Lupus ErythematosusRecruitingAZNLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2034Sponsor estimateNo phase registeredNCT06941025Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry...Chiesi Farmaceutici S.p.A. · Fabry DiseaseRecruitingICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 1NCT07915297Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)Luminance Biosciences Inc · Metastatic Breast CancerNot yet recruitingICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2030Sponsor estimateNo phase registeredNCT06252753Observational Study Protocol: LIVER-RAstraZeneca · Hepatobiliary CancersRecruitingAZNLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 28, 2025ActualPhase 2NCT05997264Anthrax AV7909 Boost Evaluation StudyBiomedical Advanced Research and Development Authority · AnthraxCompletedICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2029Sponsor estimatePhase 3NCT07647328A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerAstraZeneca · ER-Positive HER2-Negative Breast CancerRecruitingAZNLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2025ActualPhase 2NCT06560151Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03...Biomedical Advanced Research and Development Authority · InfluenzaCompletedICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 25, 2025ActualPhase 4NCT06385509A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 MonthsTolmar Inc. · HypogonadismCompletedICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 1/Phase 2NCT05322590BXQ-350 in Newly Diagnosed Metastatic Colorectal CarcinomaBexion Pharmaceuticals, Inc. · Metastatic Colorectal CarcinomaActive, not recruitingICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2032Sponsor estimateNo phase registeredNCT06564974Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMITCatalyst Pharmaceuticals, Inc. · Duchenne Muscular DystrophyRecruitingCPRXLeadICLRCollaboratorMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2031Sponsor estimateNo phase registeredNCT06465810Non-interventional Study of Patients With Transthyretin (ATTR) AmyloidosisAstraZeneca · Transthyretin AmyloidosisRecruitingAZNLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2029Sponsor estimatePhase 2NCT07514338Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial DiseasePharming Technologies B.V. · Mitochondrial DiseasesRecruitingICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 27, 2030Sponsor estimatePhase 3NCT06716606A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With...GlaxoSmithKline · Connective Tissue DiseasesRecruitingGSKLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2035Sponsor estimateNo phase registeredNCT07205666The Eplontersen Pregnancy and Lactation Outcomes StudyAstraZeneca · Transthyretin AmyloidosisRecruitingAZNLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimatePhase 2/Phase 3NCT06328608A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseChiesi Farmaceutici S.p.A. · Fabry DiseaseRecruitingICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2026ActualPhase 3NCT04620239ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudySteba Biotech S.A. · Transitional Cell Cancer of Renal Pelvis and UreterActive, not recruitingICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2025ActualPhase 2NCT04844866Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma PatientsMiltenyi Biomedicine GmbH · Diffuse Large B-cell LymphomaRecruitingICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 18, 2022ActualPhase 1NCT04883333A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy AdultsLEO Pharma · HealthyCompletedICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT07199569Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsBavarian Nordic · Monkeypox (Mpox)Active, not recruitingICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2024ActualNo phase registeredNCT05361486Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in PeruMedicines for Malaria Venture · Malaria, VivaxCompletedICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 80 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner